Literature DB >> 25929684

Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice.

Roberto Volpe1, Gianluca Sotis.   

Abstract

Cardiometabolic risk factors, such as hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, diabetes, and arterial hypertension, are major predictors of the premature development of cardiovascular diseases (CVD). Since CVD prevention needs a life-course approach, beyond dietary and pharmacological treatment, non-pharmacological treatment should be considered an important alternative for patients in primary prevention with mild-moderate cardiometabolic risk factors at low-moderate global risk of CVD. Several functional foods and nutraceuticals are efficacious, safe and well tolerated. However, only some (monacolins of red yeast rice and omega-3 fatty acids) have showed, in long-term randomized clinical trials, a reduction of cardiovascular events.

Entities:  

Mesh:

Year:  2015        PMID: 25929684     DOI: 10.1007/s40292-015-0092-5

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  20 in total

1.  Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial.

Authors:  A F G Cicero; V De Sando; R Izzo; A Vasta; A Trimarco; C Borghi
Journal:  Complement Ther Clin Pract       Date:  2012-03-31       Impact factor: 2.446

Review 2.  Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.

Authors:  Javier Delgado-Lista; Pablo Perez-Martinez; Jose Lopez-Miranda; Francisco Perez-Jimenez
Journal:  Br J Nutr       Date:  2012-06       Impact factor: 3.718

Review 3.  Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals.

Authors:  Arrigo F G Cicero; Claudio Borghi
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

Review 4.  Nutraceuticals for metabolic syndrome management: from laboratory to benchside.

Authors:  Arrigo F Cicero; Elisa Tartagni; Sibel Ertek
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

5.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

Authors: 
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

Review 6.  Nutraceuticals in diabetes and metabolic syndrome.

Authors:  Giovanni Davì; Francesca Santilli; Carlo Patrono
Journal:  Cardiovasc Ther       Date:  2010-08       Impact factor: 3.023

7.  [The global cardiovascular risk chart].

Authors:  Simona Giampaoli; Luigi Palmieri; Paolo Chiodini; Giancarlo Cesana; Marco Ferrario; Salvatore Panico; Lorenza Pilotto; Roberto Sega; Diego Vanuzzo
Journal:  Ital Heart J Suppl       Date:  2004-03

8.  Lifestyle-related risk factors, smoking status and cardiovascular disease.

Authors:  Renata Giudice; Raffaele Izzo; Maria Virgina Manzi; Giampiero Pagnano; Mario Santoro; Maria Assunta Elena Rao; Gianfranco Di Renzo; Nicola De Luca; Valentina Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-06-01

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

View more
  9 in total

1.  Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product.

Authors:  Arrigo Francesco Giuseppe Cicero; Federica Fogacci; Martino Morbini; Alessandro Colletti; Marilisa Bove; Maddalena Veronesi; Marina Giovannini; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-23

2.  To Nutraceuticals and Back: Rethinking a Concept.

Authors:  Antonello Santini; Ettore Novellino
Journal:  Foods       Date:  2017-09-05

Review 3.  Nutraceuticals: opening the debate for a regulatory framework.

Authors:  Antonello Santini; Silvia Miriam Cammarata; Giacomo Capone; Angela Ianaro; Gian Carlo Tenore; Luca Pani; Ettore Novellino
Journal:  Br J Clin Pharmacol       Date:  2018-02-14       Impact factor: 4.335

4.  LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia.

Authors:  S Magno; G Ceccarini; C Pelosini; R Jaccheri; J Vitti; P Fierabracci; G Salvetti; G Airoldi; M Minale; G Saponati; F Santini
Journal:  Lipids Health Dis       Date:  2018-05-24       Impact factor: 3.876

Review 5.  Nutraceuticals in hypercholesterolaemia: an overview.

Authors:  Antonello Santini; Ettore Novellino
Journal:  Br J Pharmacol       Date:  2016-10-29       Impact factor: 8.739

6.  Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial.

Authors:  Arrigo Francesco Giuseppe Cicero; Alessandro Colletti; Federica Fogacci; Marilisa Bove; Martina Rosticci; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-06-23

Review 7.  Role of cholesterol and sphingolipids in brain development and neurological diseases.

Authors:  Ghulam Hussain; Jing Wang; Azhar Rasul; Haseeb Anwar; Ali Imran; Muhammad Qasim; Shamaila Zafar; Syed Kashif Shahid Kamran; Aroona Razzaq; Nimra Aziz; Waseem Ahmad; Asghar Shabbir; Javed Iqbal; Shahid Mahmood Baig; Tao Sun
Journal:  Lipids Health Dis       Date:  2019-01-25       Impact factor: 3.876

Review 8.  Nutraceuticals in Chronic Coronary Syndromes: Preclinical Data and Translational Experiences.

Authors:  Chiara Tognola; Maloberti Alessandro; Martina Milani; Iside Cartella; Giovanni Tavecchia; Enzo Grasso; Jinwey Sun; Cristina Giannattasio
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-10-30

9.  The Modulation of PCSK9 and LDLR by Supercritical CO2 Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study.

Authors:  Stefania Sut; Irene Ferrarese; Maria Giovanna Lupo; Nicola De Zordi; Elisa Tripicchio; Nicola Ferri; Stefano Dall' Acqua
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.